Aras Azadian

A few months ago, Benzinga visited several countries in South America and subsequently published an article explaining why cannabis investors’ interest in the region, especially in Colombia, was about to spike. In the weeks that followed, numerous U.S. and Canada-based marijuana companies...

A shortened week brought less cannabis news than usual, providing the people in the industry with a chance to exhale and look back at the convoluted weeks leading up to the Fourth of July holiday.  We did witness some relevant action. Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) reported...

Shares of GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) were halted Thursday, ahead of a Food and Drug Administration vote on the company's cannabis-derived drug Epidiolex. Trading resumed after the FDA advisory panel voted unanimously in favor of approving the medicine for the treatment of two...

While reporting for a book on the cannabis business I recently finished writing, I realized many people don't differentiate smoking weed from using cannabis. “Isn’t it the same?” is the question I was asked far too often. The answer: certainly not. Smoking is just one of many...

Medical journal The Lancet published an article Wednesday that could mold the future of cannabis-derived therapeutics. The piece in question featured results from GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) and Greenwich Biosciences’ Phase 3 study of Epidiolex — an oral cannabidiol...

As a cannabis-focused company, Avicanna did not know what the outcome would be when it applied to be part of JLABS @ Toronto. Yet, the company was delighted to make it, CEO Aras Azadian and LATAM Vice President Lucas Nosiglia told Benzinga in a recent interview. A few things became clear early in...